Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut

Trial Profile

Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEOPLE
  • Sponsors DBV Technologies
  • Most Recent Events

    • 20 Feb 2024 According to DBV media release, the company to present data from this trial in collaboration with Icahn School of Medicine at Mount Sinai and Beckman Coulter Life Sciences at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C.
    • 04 Dec 2022 This trial has been discontinued in Ireland (Date of the global end of the trial: 12-Oct-2022), according to the European Clinical Trials Database record.
    • 17 Nov 2022 This trial has been discontinued in Germany (Date of the global end of the trial: 12-Oct-2022), according to the European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top